BioNTech

BioNTech logo
🇩🇪Germany
Ownership
Public
Employees
6.1K
Market Cap
$20.7B
Website
http://www.biontech.de
Introduction

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in M...

Clinical Trials
Related News

A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Phase 1
Active, not recruiting
Conditions
Malaria
Interventions
Other: Placebo
Biological: BNT165e
First Posted Date
2023-10-06
Last Posted Date
2024-11-07
Lead Sponsor
BioNTech SE
Target Recruit Count
138
Registration Number
NCT06069544
Locations
🇺🇸

AMR Tempe, Tempe, Arizona, United States

🇺🇸

University of Maryland, Center for Vaccine Development, Baltimore, Maryland, United States

🇺🇸

AMR Las Vegas, Las Vegas, Nevada, United States

and more 2 locations

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

First Posted Date
2023-08-18
Last Posted Date
2024-07-05
Lead Sponsor
BioNTech SE
Target Recruit Count
940
Registration Number
NCT05997290
Locations
🇺🇸

Kentucky Pediatric/ Adult Research, Bardstown, Kentucky, United States

🇺🇸

M3 Wake Research, Inc., Raleigh, North Carolina, United States

🇺🇸

Bio-Kinetic Clinical Applications LLC DBA QPS_MO (Patient Screening Only), Springfield, Missouri, United States

and more 33 locations

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

Phase 1
Recruiting
Conditions
Monkeypox
Interventions
Biological: BNT166a
First Posted Date
2023-08-14
Last Posted Date
2024-12-03
Lead Sponsor
BioNTech SE
Target Recruit Count
96
Registration Number
NCT05988203
Locations
🇬🇧

Medicine Evaluation Unit Ltd, The Langley Building, Wythenshawe Hospital, Manchester, United Kingdom

🇺🇸

California Research Foundation, San Diego, California, United States

🇺🇸

Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

and more 5 locations

A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children

First Posted Date
2022-11-29
Last Posted Date
2024-03-18
Lead Sponsor
BioNTech SE
Registration Number
NCT05630352

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

First Posted Date
2022-10-27
Last Posted Date
2024-10-18
Lead Sponsor
BioNTech SE
Target Recruit Count
1019
Registration Number
NCT05596734
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

DBC Research USA, Pembroke Pines, Florida, United States

🇺🇸

Pioneer Heart Institute, Lincoln, Nebraska, United States

and more 50 locations

Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria

Phase 1
Completed
Conditions
Malaria
Interventions
Other: Placebo
Biological: BNT165b1
First Posted Date
2022-10-14
Last Posted Date
2024-10-01
Lead Sponsor
BioNTech SE
Target Recruit Count
60
Registration Number
NCT05581641
Locations
🇺🇸

Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

🇺🇸

University of Maryland, Center for Vaccine Development, Baltimore, Maryland, United States

🇺🇸

Clinical Trials of Texas, Inc., San Antonio, Texas, United States

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers

Phase 1
Active, not recruiting
Conditions
Tuberculosis
Interventions
Biological: BNT164a1
Biological: BNT164b1
Other: Placebo
First Posted Date
2022-09-21
Last Posted Date
2024-10-14
Lead Sponsor
BioNTech SE
Target Recruit Count
732
Registration Number
NCT05547464
Locations
🇿🇦

Centre for Lung Infection and Immunity UCT Lung Institute, Cape Town, South Africa

🇿🇦

Desmond Tutu Health Foundation - Masiphumele Research Office, Cape Town, South Africa

🇿🇦

The Aurum Institute Tembisa CRC Clinic 4, Tembisa, South Africa

and more 3 locations

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

First Posted Date
2022-09-16
Last Posted Date
2024-05-14
Lead Sponsor
BioNTech SE
Target Recruit Count
3692
Registration Number
NCT05543616
Locations
🇺🇸

Kaiser Permanente, Los Angeles, California, United States

🇺🇸

Emory Children's Center, Atlanta, Georgia, United States

🇺🇸

Emory University School of Medicine, Atlanta, Georgia, United States

and more 103 locations

Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People

First Posted Date
2022-09-15
Last Posted Date
2024-10-14
Lead Sponsor
BioNTech SE
Target Recruit Count
383
Registration Number
NCT05541861
Locations
🇺🇸

Alliance for Multispecialty Research, LLC, Knoxville, Tennessee, United States

🇺🇸

Clinical Research Consulting, LLC, Milford, Connecticut, United States

🇺🇸

Diablo Clinical Research, Inc., Walnut Creek, California, United States

and more 13 locations

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

Phase 1
Active, not recruiting
Conditions
Tuberculosis
Interventions
Other: Placebo
Biological: BNT164a1
Biological: BNT164b1
First Posted Date
2022-09-13
Last Posted Date
2024-10-24
Lead Sponsor
BioNTech SE
Target Recruit Count
120
Registration Number
NCT05537038
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

🇩🇪

emovis GmbH, Berlin, Germany

🇩🇪

CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy